Functional imaging of colorectal cancer angiogenesis

Lancet Oncology

Volumn 8, Issue 3, 2007, Pages 245-255

  Goh, Vicky ^a   Padhani, Anwar R ^a   Rasheed, Shahnawaz ^b  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

^b ST MARK S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BIBF 1120; CA 4P; CONTRAST MEDIUM; GADOLINIUM; IODINE; N ACETYLCOLCHINOL PHOSPHATE; SUNITINIB; UNCLASSIFIED DRUG; VANDETANIB; VASCULAR TARGETING AGENT; VATALANIB;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CANCER STAGING; CANCER THERAPY; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DRUG DOSE ESCALATION; ECHOGRAPHY; HUMAN; IN VIVO STUDY; INTERMETHOD COMPARISON; MONOTHERAPY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RECTUM CANCER; REVIEW; TUMOR VASCULARIZATION;

COLORECTAL NEOPLASMS; HUMANS; MAGNETIC RESONANCE IMAGING; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33847173683     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(07)70075-X     Document Type: Review

References (90)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 285 (1971) 1182-1186
2. Rak J., Mitsuhashi Y., Bayko L., et al. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 55 (1995) 4575-4580
3. Ajiki T., Fujimori T., Ikehara H., et al. K-ras gene mutation related to histological atypias in human colorectal adenomas. Biotech Histochem 70 (1995) 90-94
4. Konerding M., Fait E., and Gaumann A. 3D microvascular architecture of pre-cancerous lesions and invasive carcinomas of the colon. Br J Cancer 84 (2001) 1354-1362
5. Jain R. Transport of molecules across tumor vasculature. Cancer Metastasis Rev 6 (1987) 559-593
6. Dvorak H., Nagy J., Feng D., et al. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr Top Microbiol Immunol 237 (1999) 97-132
7. Eberhard A., Kahlert S., Goede V., et al. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res 60 (2000) 1388-1393
8. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
9. Jain R., Duda D., Clark J., and Loeffler J. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 3 (2006) 24-40
10. Folkman J. Fundamental concepts of the angiogenic process. Curr Mol Med 3 (2003) 643-651
11. Barbera-Guillem E., Nyhus J., Wolford C., et al. Vascular endothelial growth factor secretion by tumor-infiltrating macrophages essentially supports tumor angiogenesis, and IgG immune complexes potentiate the process. Cancer Res 62 (2002) 7042-7049
12. Duff S., Li C., Jeziorska M., et al. Vascular endothelial growth factors C and D and lymphangiogenesis in gastrointestinal tract malignancy. Br J Cancer 89 (2003) 426-430
13. Tabara H., Kohno H., Dhar D., et al. Concurrent expression of angiogenic growth factors and neovascularization during tumourigenesis in colorectal carcinoma patients. Acta Oncol 40 (2001) 622-628
14. Kaio E., Tanaka S., Kitadai Y., et al. Clinical significance of angiogenic factor expression at the deepest invasive site of advanced colorectal carcinoma. Oncology 64 (2003) 61-73
15. Furudoi A., Tanaka S., Haruma K., et al. Clinical significance of vascular endothelial growth factor C expression and angiogenesis at the deepest invasive site of advanced colorectal carcinoma. Oncology 62 (2002) 157-166
16. Kaklamanis L., Trichas M., Amarantidis K., et al. VEGF expression in the colorectal adenoma-carcinoma sequence. Oncol Res 15 (2006) 445-451
17. Kondo Y., Arii S., Furutani M., et al. Implication of vascular endothelial growth factor p53 status for angiogenesis in noninvasive colorectal carcinoma. Cancer 88 (2000) 1820-1827
18. George M., Tutton M., Janssen F., et al. VEGF-A, VEGF-C and VEGF-D in colorectal cancer progression. Neoplasia 3 (2001) 420-427
19. Des Guetz G., Uzzan B., Nicolas P., et al. Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br J Cancer 94 (2006) 1823-1832
20. Werther K., Christensen I., Brunner N., and Nielsen H. Soluble vascular endothelial growth factor levels in patients with primary colorectal carcinoma. The Danish RANX05 Colorectal Cancer Study Group. Eur J Surg Oncol 26 (2000) 657-662
21. Takahashi Y., Tucker S., Kitadai Y., et al. Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node negative colon cancer. Arch Surg 132 (1997) 541-546
22. Soumaoro L., Uetake H., Takagi Y., et al. Coexpression of VEGF-C and Cox-2 in human colorectal cancer and its association with lymph node metastasis. Dis Colon Rectum 49 (2006) 392-398
23. Tomisaki S., Ohno S., Ichiyoshi Y., et al. Microvessel quantification and its possible relation with liver metastasis in colorectal cancer. Cancer 77 Suppl (1996) 1722-1728
24. Takayebashi Y., Aklyama S., Yamada K., et al. Angiogenesis as an unfavorable prognostic factor in human colorectal cancer. Cancer 77 (1996) 1722-1728
25. Saclarides T., Speziale N., Drab E., et al. Tumor angiogenesis and rectal carcinoma. Dis Colon Rectum 37 (1994) 921-926
26. Frank R., Saclarides T., Leurgens S., et al. Tumor angiogenesis as predictor of recurrence and survival in patients with node negative colon cancer. Ann Surg 222 (1995) 695-699
27. Tanigawa N., Amaya H., Matsumura M., et al. Tumor angiogenesis and mode of metastasis in patients with colorectal cancer. Cancer Res 57 (1997) 1043-1046
28. Choi H., Hyun M., Jung G., et al. Tumor angiogenesis as a prognostic predictor in colorectal carcinoma with special reference to mode of metastasis and recurrence. Oncology 55 (1998) 575-581
29. Vermeulen P., Van den Eynden G., Huget P., et al. Prospective study of intratumoral microvessel density, p53 expression, and survival in colorectal cancer. Br J Cancer 79 (1999) 316-322
30. Fontanini G., Lucchi M., Vignati S., et al. Angiogenesis as a prognostic indicator of survival in non-small cell lung cancer. J Natl Cancer Inst 89 (1997) 881-886
31. Cooper R., Wilks D., Logue J., et al. High tumour angiogenesis is associated with poorer survival in carcinoma of the cervix treated with radiotherapy. Clin Cancer Res 4 (1998) 2795-2800
32. Weidner N., Semple J., Welch W., and Folkman J. Tumor angiogenesis and metastasis- correlation in invasive breast cancer. N Eng J Med 324 (1991) 1-8
33. Bossi P., Viale G., Lee A., et al. Angiogenesis in colorectal tumors: microvessel quantitation in adenomas and carcinomas with clinicopathological correlations. Cancer Res 55 (1995) 5049-5053
34. Pritchard A., Chatterjee T., Wilkinson M., et al. Evidence for a weak angiogenic response to human colorectal cancers. Br J Cancer 71 (1995) 1081-1086
35. Oh-E H., Tanaka S., Kitadai Y., et al. Angiogenesis at the site of deepest penetration predicts lymph node metastasis of submucosal colorectal cancer. Dis Colon Rectum 44 (2001) 1129-1136
36. Engel C., Bennett S., Chambers A., et al. Tumor angiogenesis predicts recurrence in invasive colorectal cancer when controlled for Dukes staging. Am J Surg Pathol 20 (1996) 1260-1265
37. Cianchi F., Palomba A., Messerini L., et al. Tumor angiogenesis in lymph node negative rectal cancer: correlation with clinicopathological parameters and prognosis. Ann Surg Oncol 9 (2002) 20-26
38. Lindmark G., Gerdin B., Sundberg C., et al. Prognostic significance of microvascular count in colorectal cancer. J Clin Oncol 14 (1996) 461-466
39. Banner B., Whitehouse R., Baker S., and Swanson R. Tumor angiogenesis in Stage II colorectal carcinoma: association with survival. Am J Clin Pathol 109 (1998) 733-737
40. Abdalla S., Behzad F., Bsharah S., et al. Prognostic relevance of microvessel density in colorectal tumours. Oncol Rep 6 (1999) 839-842
41. Mooteri S., Rubin D., Leurgans S., et al. Tumor angiogenesis in primary and metastatic colorectal cancers. Dis Colon Rectum 39 (1996) 1073-1080
42. Berney C., Yang J., Fisher R., et al. Vascular endothelial growth factor expression is reduced in liver metastasis from colorectal cancer and correlates with urokinase-type plasminogen activator. Anticancer Res 18 (1998) 973-977
43. Offersen B., Borre M., and Overgaard J. Quantification of angiogenesis as a prognostic marker in human carcinomas: a critical evaluation of histopathological methods for estimation of vascular density. Eur J Cancer 39 (2003) 881-890
44. Fox S., Leek R., Smith K., Hollyer J., et al. Tumor angiogenesis in node-negative breast carcinomas-relationship with epidermal growth factor receptor, estrogen receptor, and survival. Breast Cancer Res Treat 29 (1994) 109-116
45. Vermeulen P., Gasparini G., Fox S., et al. Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur J Cancer 38 (2002) 1564-1579
46. Jubb A., Hurwitz H., Bai W., et al. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol 24 (2006) 217-227
47. Kuszyk B., Corl F., Franano F., et al. Tumor Transport physiology: implications for imaging and imaging guided therapy. AJR Am J Roentgenol 177 (2001) 747-753
48. Hlatky L., Hahnfeldt P., and Folkman J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst 94 (2002) 883-893
49. Hanahan D., and Wenberg R. The hallmarks of cancer. Cell 100 (2000) 57-70
50. Leach M., Brindle K., Evelhoch J., et al. The assessment of antiangiogenic and antivascular therapies in early stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer 92 (2005) 1599-1610
51. Lankester KJ, Taylor NJ, Stirling JJ, et al. Dynamic MRI for imaging tumor microvasculature: comparison of susceptibility and relaxivity techniques in pelvic tumors. J Magn Reson Imaging (in press).
52. Willett C., Boucher Y., di Tomaso E., et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10 (2004) 145-147
53. Morgan B., Thomas A., Drevs J., et al. Dynamic contrast enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 21 (2003) 3955-3964
54. Galbraith S., Maxwell R., Lodge M., et al. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 21 (2003) 2831-2842
55. Tuncbilek N., Karakas H., and Altaner S. Dynamic MRI in indirect estimation of microvessel density, histologic grade, and prognosis in colorectal adenocarcinomas. Abdom Imaging 29 (2004) 166-172
56. George M., Dzik-Jurasz A., Padhani A., et al. Non invasive methods of assessing angiogenesis and their value in predicting response to treatment in colorectal cancer. Br J Surg 88 (2001) 1628-1636
57. Atkin G., Taylor N., Daley F., et al. Dynamic contrast-enhanced magnetic resonance imaging is a poor measure of colorectal cancer angiogenesis. Br J Surg 93 (2006) 992-1000
58. Purdie T., Henderson E., and Lee T. Functional CT imaging of angiogenesis in rabbit VX2 soft-tissue tumor. Phys Med Biol 46 (2001) 3161-3175
59. Cenic A., Nabavi D., Craen R., et al. Dynamic CT measurement of cerebral blood flow: a validation study. AJNR Am J Neuroradiol 20 (1999) 63-73
60. Wintermark M., Thiran J., Maeder P., et al. Simultaneous measurement of regional cerebral blood flow by perfusion CT and stable xenon CT: a validation study. AJNR Am J Neuroradiol 22 (2001) 905-914
61. Gillard J., Minhas P., Hayball M., et al. Assessment of quantitative computed tomographic cerebral perfusion imaging with H2(15)O positron emission tomography. Neurol Res 22 (2000) 457-464
62. Goh V., Halligan S., Hugill J., and Bartram C. Quantitative assessment of colorectal cancer perfusion using dynamic contrast enhanced MDCT: reproducibility and comparison with normal muscle perfusion. AJR Am J Roentgenol 187 (2006) 164-169
63. Goh V., Halligan S., Hugill J., and Bartram C. Quantitative colorectal cancer perfusion measurements using MDCT: inter and intra-observer agreement. AJR Am J Roentogenol 185 (2005) 225-231
64. Sahani D., Kalva S., Hamberg L., et al. Assessing tumor perfusion and treatment response in rectal cancer with multisection CT: initial observations. Radiology 234 (2005) 785-792
65. Lee T., Purdie T., and Stewart E. CT imaging of angiogenesis. Q J Nucl Med 41 (2003) 171-187
66. Yi C., Lee K., Kim E., et al. Solitary pulmonary nodules: dynamic enhanced multidetector row CT study and comparison with vascular endothelial growth factor and microvessel density. Radiology 233 (2004) 191-199
67. Tateishi U., Kusumoto M., Nishihara H., et al. Contrast enhanced dynamic computed tomography for the evaluation of angiogenesis in patients with lung carcinoma. Cancer 95 (2002) 835-842
68. Wang J., Min P., Wang P., et al. Dynamic CT evaluation of tumor vascularity in renal cell carcinoma. AJR Am J Roentgenol 186 (2006) 1423-1430
69. Li Z., Meng Q., Sun C., et al. Tumor angiogenesis and dynamic CT in colorectal carcinoma: radiologic-pathologic correlation. World J Gastroenterol 11 (2005) 1287-1291
70. McCarville M., Streck C., Dickson P., et al. Angiogenesis inhibitors in a murine neuroblastoma model: quantitative assessment of intratumoral blood flow with contrast enhanced grey scale US. Radiology 240 (2006) 73-81
71. Ogura O., Takebayashi Y., Sameshima T., et al. Pre-operative assessment of vascularity by color Doppler ultrasonography in human rectal carcinoma. Dis Colon Rectum 44 (2001) 538-548
72. Goh V., Halligan S., Taylor S., et al. Differentiating between diverticulitis and colorectal cancer: quantitative CT perfusion measurements versus morphologic criteria - initial experience. Radiology 242 (2007) 456-462
73. Hermans R., Meijerink M., Van den Bogaert W., et al. Tumor perfusion rate determined non-invasively by dynamic computed tomography predicts outcome in head-and-neck cancer after radiotherapy. Int J Radiat Oncol Biol Phys 57 (2003) 1351-1356
74. Mayr N., Yuh W., Arnholt J., et al. Pixel analysis of MR perfusion imaging in predicting radiation therapy outcome in cervical cancer. J Magn Reson Imaging 12 (2000) 1027-1033
75. Leggett D., Kelley B., Bunce I., and Miles K. Colorectal cancer: diagnostic potential of CT measurements of hepatic perfusion and implications for contrast enhancement protocols. Radiology 205 (1997) 716-720
76. Miles K., Leggett D., Kelley B., et al. In vivo assessment of neovascularisation of liver metastases using perfusion CT. Br J Radiol 71 (1998) 276-281
77. Cuenod C., Leconte I., Siauve N., et al. Early changes in liver perfusion caused by occult metastases in rats: detection with quantitative CT. Radiology 218 (2001) 556-561
78. Chen C., Cheng Y., Liang J., et al. Color Doppler vascularity index can predict distant metastasis and survival in colon cancer patients. Cancer Res 60 (2000) 2892-2897
79. Leen E., Goldberg J., Angerson W., and McArdle C. Potential role of doppler perfusion index in selection of patients with colorectal cancer for adjuvant chemotherapy. Lancet 355 (2000) 34-37
80. Fowler R., Harris K., Swift S., et al. Hepatic Doppler perfusion index: measurement in nine healthy volunteers. Radiology 209 (1998) 867
81. Thomas A., Morgan B., Horsfield M., et al. Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. J Clin Oncol 23 (2005) 4162-4171
82. Garcia-Barros M., Paris F., Cordon-Cardo C., et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300 (2003) 1155-1159
83. Pena L., Fuks Z., and Kolesnick R. Radiation-induced apoptosis of endothelial cells in the murine central nervous system: protection by fibroblast growth factor and sphingomyelinase deficiency. Cancer Res 60 (2000) 321-327
84. Moeller B., Cao Y., Li C., and Dewhirst M. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: Role of reoxygenation, free radicals, and stress granules. Cancer Cell 5 (2004) 429-441
85. De Vries A., Griebel J., Kremser C., et al. Monitoring of tumor microcirculation during fractionated radiation therapy in patients with rectal carcinoma: preliminary results and implications for therapy. Radiology 217 (2000) 385-391
86. DeVries A., Griebel J., Kremser C., et al. Tumor microcirculation evaluated by dynamic contrast enhanced magnetic resonance imaging predicts therapy outcome for primary rectal carcinoma. Cancer Res 61 (2001) 2513-2516
87. Lankester K., Taylor N., Stirling J., et al. Effects of platinum/taxane based chemotherapy on acute perfusion in human pelvic tumours measured by dynamic MRI. Br J Cancer 93 (2005) 979-985
88. Iinuma G., Moriyama N., Satake M., et al. Vascular virtual endoluminal visualization of invasive colorectal cancer on MDCT colonography. AJR Am J Roentgenol 184 (2005) 1194-1198
89. Funama Y., Awai K., Nakayama Y., et al. Radiation dose reduction without degradation of low-contrast detectability at abdominal multisection CT with a low-tube voltage technique: phantom study. Radiology 237 (2005) 905-910
90. Kim J., Kim H., Lee K., et al. Solitary pulmonary nodules: a comparative study evaluated with contrast-enhanced dynamic MR imaging and CT. J Comput Assist Tomogr 28 (2004) 766-775